… Preliminary phase II results confirmed docetaxel's activity against breast, non-small-cell and
… retention seen after repeated docetaxel courses. Studies are evaluating docetaxel in various …

… In vitro and in vivo, docetaxel has antineoplastic activity against a wide … of docetaxel are
linear at clinically relevant doses and are consistent with a three-compartment model. Docetaxel …

… docetaxel (Taxotere) is formulated in the nonionic surfactant polysorbate 80 (Tween 80). Early
in the clinical development of docetaxel, it became clear that docetaxel … of docetaxel. More …

… In vivo, 1, 2, and 3 nM docetaxel and 4, 8, and 12 nM paclitaxel … docetaxel and paclitaxel
doses selectively cause organic and functional damage of endothelial cells and that docetaxel …

… Docetaxel has significant activity in breast, non-small-cell lung, ovarian and head and neck
cancers. Docetaxel … III studies, and the disposition of docetaxel after such treatment is best …

Docetaxel is an effective treatment approved in five key … of the published work on specific
docetaxel-related side effects … to the majority of docetaxel regimens and indications and of …

… docetaxel or docetaxel-based combination regimens. Data from two adjuvant trials have shown
a survival benefit with the addition of docetaxel … III trials with docetaxel in the treatment of …

Introduction: Docetaxel (DTX) has been proven as one of the most important cytotoxic agents,
and its clinical efcacy against many cancers is superior to paclitaxel. DTX in commercial …

… Docetaxel is a taxoid which is currently in phase II/III clinical … In vitro, the docetaxel
concentrations required to reduce … found very sensitive to iv docetaxel and complete regressions …

… docetaxel in this setting. Recent preclinical studies have improved our understanding of
docetaxel’… The antitumor activity of docetaxel in patients with prostate cancer and other solid tue …